The AHA provided recommendations to the Food and Drug Administration Oct. 19 on potential regulatory frameworks for generative artificial intelligence-enabled medical devices. The AHA expressed support for a flexible, risk-based regulatory framework that protects patients without impeding responsible innovation. Among its suggestions, the AHA recommended the FDA refine the proposed risk heuristic for evaluating the risk of GenAI applications and provide labelling guidance on “informational action directing” devices versus “action taking” devices. The AHA also requested the agency to align premarket clearance and post-deployment evaluation and monitoring activities under a total product lifecycle and clarify that GenAI-enabled clinical decision support and administrative tools are not subject to FDA oversight. 

Headline
The AHA will host a webinar Dec. 2 at 1 p.m. ET that will explore strategies on protecting patient care, identifying critical systems that must remain…
Headline
In comments provided Nov. 16 to majority and minority leaders of the House and Senate, the AHA requested Congress to act on key priorities for hospitals and…
Headline
An FBI report released Nov. 13 details actions by cyber actors weaponizing ARTEX, an open-source, large language model-driven agentic artificial intelligence…
Headline
The AHA will host a webinar Dec. 1 at 1 p.m. ET on how to create and build an effective artificial intelligence training program. Attendees will learn how to…
Headline
A Gallup survey published Nov. 9 on patient comfort with artificial intelligence in care found that 56% of U.S. adults who visited a primary care provider in…
Headline
The Centers for Medicare & Medicaid Services Nov. 9 announced allocations for the second year of the Rural Health Transformation Program, which will award…